Angiotension type 1 receptor blockade versus ACE inhibition in the treatment of heart failure: Results of 3 clinical trials

Angiotension-converting enzyme (ACE) inhibitors are of critical importance for the treatment of patients with heart failure. Intensive study has shown that ACE inhibitors significantly reduce mortality and morbidity and are well tolerated by the vast majority of patients with heart failure.^1-4

The role of angiotension type 1 receptor blockers (ARBs) as an alternative to ACE inhibition or as an additional means of treatment in patients with heart failure has been evaluated in three recent trials: ELITE (Evaluation of Losartan in the Elderly), RESOLVD (Randomized Evaluation of Strategies for Left Ventricular Dysfunction), and ELITE II.^5-7

References are listed at the end of the Data Alert.

DA3.ppt

Download DA3.ppt (7 slides - 0.3MB)

Data_Alert.pdf (0.3MB)

ACE Angiotension blockade critical enzyme inhibition

Related at vwbg.org

Data and Commentary: The BANFF Study

Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease

J Am Coll Cardiol.

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection

This monograph, ACE Inhibition in CAD Patients: Expanding the Reach of Cardioprotection , which is being offered as part of a series of continuing medical education activities from the University of Florida College of Medicine.

More related